Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

Abstract:

In Brief:

Arzoxifene is a newer-generation SERM developed for the prevention and treatment of osteoporosis as well as for the prevention of breast cancer. This article summarizes the gynecological effects of Arzoxifene on postmenopausal women.

Abstract:

In Brief:

In a randomized trial, postmenopausal women with osteoporosis received 5 years of treatment with lasofoxifene or placebo. Treatment with lasofoxifene resulted in benign endometrial changes that did not seem to increase the risk for endometrial cancer or hyperplasia in postmenopausal women.

Abstract:

In Brief:

Endometrial safety has been an important consideration in the clinical development of selective estrogen receptor modulators with potentially improved benefit-risk profiles. Promising results have been observed with the targeted development of newer and more tissue-specific selective estrogen receptor modulators, many of which are under investigation for postmenopausal osteoporosis.

Abstract:

In Brief:

Raloxifene is a selective estrogen receptor modulator long used for prevention and treatment of osteoporosis, more recently approved for breast cancer risk reduction in osteoporotic women as well as women at high risk for breast cancer. This article reviews the effects of raloxifene on multiple organ systems.

Abstract:

In Brief:

The incidence of self-reported urinary incontinence, rated as "mild," "moderate," or "severe," was determined at baseline and after 3 years of treatment with placebo, raloxifene 60 or 150 mg/d, or conjugated equine estrogens 0.625 mg/d in 619 postmenopausal women with a prior hysterectomy. Whereas the baseline prevalence of urinary incontinence was similar between groups, the percentage of women reporting new or worsening urinary incontinence at 3 years was greater in the conjugated equine estrogens group, compared with placebo, raloxifene 60 mg/d, and raloxifene 150 mg/d.